Arbitrage Opportunity MMJ / HVST - Research analysts perspective, page-5

"More familiar with MMJ", you must be mistaken. It's not an assumption, it's a fact. All MMJ Phytotech is is three (3) distinct entities, cash, and a management team. The two (2) revenue generating entities are UG (Canadian assets) and Satipharm (International, including all current Australian operations). Also, the entire management team has moved over to the Canadian entity (Andreas, etc.). So all that's left to distinguish is the final standalone corp (Phytotech Therapeutics, a research entity) and the cash. Sure, there's a possibility this shell company can hire new staff to try and turn that ~$10MM in cash into something, but the Board is more likely to just dividend it out.